Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report

Authors

  • Carolina Négrier Lourenço Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Marta Rebelo Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Elsa Gaspar Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Diniz Vieira Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • José Manuel Silva Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • J. J. Alves de Moura Serviço de Medicina II dos Hospitais da Universidade de Coimbra

Keywords:

Lipoprotein (a), LDL-cholesterol, cardiovascular risk, nicotinic acid

Abstract

Lipoprotein (a) (Lp(a)) is considered to be a cardiovascular risk
factor, and nicotinic acid is the only available drug that reduces its levels.
The authors present the case of a 44-year-old male patient with
hypercholesterolemia that responded poorly to statin therapy. After
identifying elevated Lp(a) levels combined therapy with nicotinic
acid was initiated, resulting in normalization of LDL-cholesterol
levels. The authors also make a theoretical review of Lp(a) and
nicotinic acid.

Downloads

Download data is not yet available.

References

Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004, 15:167-174.

Rosenson RS, Stein JH. Lp(a) metabolism and approach to the patient with high Lp(a) levels. UpTodate 2005;13:2.

Tsimikas S, Brilakis ES, Miller ER et al. Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. N Engl J Med 2005; 353: 46-57.

Jones GT, van Rij AM, Cole et al. et al. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem 2007 Apr; 53(4): 679-685.

Meyers CD, Kamanna VS, Kashiap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004, 15: 659-665.

Kamanna VS, Kashyap ML. Mechanism of Action of Niacin. Am J Cardiol 2008:101: 20B-26B.

Grundy SM, Cleeman JI. Merz CNB et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation.2004; 110:227-239.

Marcovina SM, Koschinsky ML, Albers JJ et al. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions. Clinical Chemistry 2003; 49(11): 1785–1796.

Vogt A, Kassner U, Hostalek U et al. E. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vascular Health and Risk Management 2007:3(4) 467–479.

Scanu AM, Bamba R. Niacin and Lipoprotein(a):Facts, Uncertainties, and Clinical Considerations. Am J Cardiol 2008;101: 44B-47B.

Canner P, Furberg CD, Terrin ML et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95: 254-257.

Brown B, et al. Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease. N Engl J Med 2001; 345: 1583-1592.

Additional Files

Published

2009-03-31

How to Cite

1.
Négrier Lourenço C, Rebelo M, Gaspar E, Vieira D, Silva JM, Alves de Moura JJ. Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report. RPMI [Internet]. 2009 Mar. 31 [cited 2024 Dec. 18];16(1):22-6. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/1380

Issue

Vol. 16 No. 1 (2009): Janeiro/ Março

Section

Case Reports

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Medicina Interna

Open Access

Most read articles by the same author(s)

1 2 > >>